Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SKG0106 is a proprietary novel recombinant adeno-associated viral vector containing a uniquely configured transgene with potent inhibition effect on intraocular neovascularization, that is being developed for the treatment of serious ophthalmic conditions including nAMD.
Lead Product(s): SKG0106
Therapeutic Area: Ophthalmology Product Name: SKG0106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
SKG0106 is a proprietary novel recombinant adeno-associated viral vector containing a uniquely configured transgene with potent inhibition effect on intraocular neovascularization, that is being developed for the treatment of serious ophthalmic conditions including nAMD.
Lead Product(s): SKG0106
Therapeutic Area: Ophthalmology Product Name: SKG0106
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023